A Randomized, Double Blind, Placebo Controlled Trial on the Effect of Rosiglitazone in Reversion of Newly Diagnosed Type 2 Diabetes to Non-Diabetic Status

Trial Profile

A Randomized, Double Blind, Placebo Controlled Trial on the Effect of Rosiglitazone in Reversion of Newly Diagnosed Type 2 Diabetes to Non-Diabetic Status

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2012 Planned number of patients changed to 80.
    • 18 Sep 2012 Additional trial identifier (ChihiCTR-TRC06000683) identified as reported by Chinese Clinical Trial Register.
    • 18 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top